Piramal Pharma Ltd

Piramal Pharma Other Announcement

Piramal Pharma Limited informed exchanges that Niche99 has independently assigned it an ESG rating of 67.1 (ESG Band: Leader), without any company engagement.

Piramal Pharma Business Update

Piramal Pharma reported that the US FDA issued a Form-483 with 7 observations following a GMP inspection of its Morpeth, UK facility.

Piramal Pharma Other Announcement

Piramal Pharma Limited received an improved ESG rating of 65 from NSE Sustainability Ratings and Analytics. The rating was assigned voluntarily based on public disclosures.

Piramal Pharma Share Pledge

Deutsche Bank AG, acting as security agent, has disclosed the re-creation of a pledge over 98.4 million shares of Piramal Pharma Limited by the borrower.

Piramal Pharma Business Update

Piramal Pharma Limited released its Sustainability Report for FY2025-26, detailing the company's ESG performance across key pillars, including business resilience and operational sustainability.

Piramal Pharma Merger & Restructuring Worth ₹76 Cr

Piramal Pharma acquired an additional 40.67% stake in Yapan Bio for ₹76 Crore. This transaction increases its total holding to 74%, making Yapan Bio a subsidiary.

Value

₹76.00 Cr

Piramal Pharma Share Pledge

Deutsche Bank AG released 98,400,000 pledged equity shares of Piramal Pharma Limited, representing a 7.39% stake. The bank continues to hold 10.54% under pledge.

Piramal Pharma Merger & Restructuring

Piramal Pharma exercised a call option to acquire an additional 41% stake in Yapan Bio, becoming its majority shareholder with a 74% stake.